Navigation Links
ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Date:8/19/2007

MISSISSAUGA, ON, Aug. 15 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Oncoscience AG (Wedel, Germany), its European partner for the development of the humanized EGFR-targeting monoclonal antibody, nimotuzumab, has recruited the 40th and final patient in its international phase III trial combining nimotuzumab with radiation for the treatment of children and adolescents suffering from diffuse intrinsic pontine glioma (DIPG). DIPG is an inoperable form of brain cancer for which treatment options are severely limited. The Phase III trial is being conducted by an international group of paediatric oncologists under the lead of principal investigator Professor Udo Bode at the University of Bonn, Germany. The primary end-point of the trial is progression-free survival with overall survival as a secondary endpoint. Nimotuzumab has been designated an Orphan Drug by the EMEA.

"Oncoscience AG is moving to complete this DIPG trial, one in a series that, if successful, will be an important component of our nimotuzumab regulatory strategy," said David Allan, Chairman and CEO of YM BioSciences. "YM has received clearance for a Canadian Phase II trial in children with recurrent DIPG for which the principal investigatory site is the Hospital for Sick Children in Toronto, an internationally recognized Centre of Excellence in paediatric medicine."

Positive European data from a completed second line 47-patient Phase II nimotuzumab monotherapy trial in recurrent pediatric glioma were most recently summarized in an oral presentation at ASCO 2007. The clinical benefi
'/>"/>

SOURCE YM BioSciences Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. Jellyfish partners for sales tracking technology
6. GE Healthcare partners with UNC on breast cancer imaging research
7. Manufacturing partnership will move into biotech and biomedical spaces
8. Fergus joins Baird Venture Partners, Caden Bio
9. Avolte Venture Partners reaches capital goal
10. NimbleGen partners with UK biotech firm
11. Big pharma seeks Wisconsin biotech partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 Envera announced ... Fermentation Manager. Mr. McErlean has an extensive background ... leadership positions throughout his career. , Mike ... very pleased to have Mike join our team”. “Mike’s ... large scale fermentation and downstream processing equipment”, ...
(Date:5/21/2013)... WEST PALM BEACH, Fla. , May 21, ... Inc. (NYSE: FCN ), the global ... and enhance their enterprise value (the "Company"), announced ... sciences focused personnel that were formerly included within ... Forensic and Litigation Consulting segment to form a ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... According to a new market ... "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, ... Share, Growth, Trends and Forecast, 2012 - 2018," the market was valued ... to grow at a CAGR of 10.1% from 2012 ... 4.7 billion in 2018. Browse the full ...
Breaking Biology Technology:Envera Appoints Michael McErlean Fermentation Manager 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5
... Ortho Biotech is pleased,with recommendations of ... Renal Drugs Advisory Committee (CRDAC) and Drug ... from the,Committees, evaluation of the use of ... failure (CRF). "Ortho Biotech supports the ...
... 11 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... Marcial of BusinessWeek, highlighted Access Pharmaceuticals in ... The article is also available,on http://www.BusinessWeek.com ... The article focused upon the major ...
... Additional Phase 3 Trials on Track for Initiation Later ... for Today at 8:30 a.m. Eastern Time -, ... ARNA ) announced today that an independent Echocardiographic,Data Safety ... to stop,the ongoing pivotal Phase 3 trial, BLOOM (Behavioral ...
Cached Biology Technology:Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 2Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 3Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 4Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 5Access Highlighted in Recent BusinessWeek Article 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 6
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... Institute is home to a rich trove of biological ... genetic Library of Congressholds over 147,000 plasmids, (circular DNA ... as well as full genome collections from numerous organisms ... A new $6.5 million grant from the National ...
... its initial appearance in New York in 1999, West Nile ... years and is now well established throughout North and South ... birds that are important hosts for the virus are abundant ... As a result, transmission of West Nile virus is highest ...
... (NSF) has awarded $3 million to Clemson University to ... sensors to monitor water quality along the entire length ... represents a ,big idea, worthy of Thomas Green Clemson, ... scientific research and education," said Clemson President James F. ...
Cached Biology News:Clearing house for DNA gets a boost 2Clearing house for DNA gets a boost 3West Nile virus transmission linked with land-use patterns and 'super-spreaders' 2West Nile virus transmission linked with land-use patterns and 'super-spreaders' 3Clemson's Intelligent River technology to provide real-time monitoring of river 2Clemson's Intelligent River technology to provide real-time monitoring of river 3Clemson's Intelligent River technology to provide real-time monitoring of river 4
Black Polypropylene 384 Round Well Plate 70/Box...
... • Heat activated ,• ... room temperature ,• Excellent specificity allows ... and secondary structures ,• Leaves an ... chemically modified form of GeneChoice DNA Polymerase ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... BioControl multichannel has the ... the single channel model.The ... allseven multichannel and five ... modules. Both pipettes have ...
Biology Products: